• HOME
  • ABOUT
    • EXECUTIVE SUMMARY
    • MANAGEMENT TEAM
    • SCIENTIFIC ADVISORY BOARD
    • R&D PARTNER
  • RESEARCH
    • CELL TECHNOLOGY
    • THE SCIENCE
    • MICROENCAPSULATION
  • GLOBAL
    • ALTUCELL BACKGROUND
    • MARKET OPPORTUNITY
    • INTELLECTUAL PROPERTY
  • BROAD VIEW
    • DIABETES
    • AUTOIMMUNE DISEASES
  • PROFILE
    • PRODUCT APPLICATIONS
    • INVESTMENT HIGHLIGHTS
    • COMPANY MILESTONES
  • PUBLICATIONS
  • CONTACT
  • Blank
  • More
    • HOME
    • ABOUT
      • EXECUTIVE SUMMARY
      • MANAGEMENT TEAM
      • SCIENTIFIC ADVISORY BOARD
      • R&D PARTNER
    • RESEARCH
      • CELL TECHNOLOGY
      • THE SCIENCE
      • MICROENCAPSULATION
    • GLOBAL
      • ALTUCELL BACKGROUND
      • MARKET OPPORTUNITY
      • INTELLECTUAL PROPERTY
    • BROAD VIEW
      • DIABETES
      • AUTOIMMUNE DISEASES
    • PROFILE
      • PRODUCT APPLICATIONS
      • INVESTMENT HIGHLIGHTS
      • COMPANY MILESTONES
    • PUBLICATIONS
    • CONTACT
    • Blank
  • HOME
  • ABOUT
    • EXECUTIVE SUMMARY
    • MANAGEMENT TEAM
    • SCIENTIFIC ADVISORY BOARD
    • R&D PARTNER
  • RESEARCH
    • CELL TECHNOLOGY
    • THE SCIENCE
    • MICROENCAPSULATION
  • GLOBAL
    • ALTUCELL BACKGROUND
    • MARKET OPPORTUNITY
    • INTELLECTUAL PROPERTY
  • BROAD VIEW
    • DIABETES
    • AUTOIMMUNE DISEASES
  • PROFILE
    • PRODUCT APPLICATIONS
    • INVESTMENT HIGHLIGHTS
    • COMPANY MILESTONES
  • PUBLICATIONS
  • CONTACT
  • Blank

INVESTMENT HIGHLIGHTS

Large target market opportunities in the diagnosis and treatment of diabetes

· Highly differentiated intellectual property base protected by a series of directly-owned (3) global patents

· Exceptional team of scientists as directors of research with established reputations in the fields of    endocrinology, diabetes, clinical trials and biomedical engineering; widely recognized in the diabetes space

· History of collaboration with influential leaders in the diabetes research and cell technology fields, as    evidenced in research contacts and investigative collaborations with major universities 

· Promising data from a series of animal studies and human subjects administered transplant with a 5 year follow-up, validating the safety and efficacy of our treatment and the micro-encapsulation method 

· Our patented technologies have broad applications; we are interested in exploring strategic partnerships that bring incremental expertise, resources, geographic reach and disease area knowledge to our platform

· Altucell sees high value in forming select, strategic collaborations 


Financial Plan

To date most of the development has been funded by the CEO & founder. The company’s results and strategic positioning based on sound science with a remarkable technical/medical team are now well positioned to make Altucell a highly attractive corporate partner with enormous licensing income potential across numerous diseases. 


* Research & Development for the next 18 months on the 3 diseases outlined in the Road Map

· Preparation of IND materials for submission to AIFA (Italian Reg. Agency)

· The head of the FDA for cell division is requesting that our Italian documents be submitted for a pre IND meeting with the FDA, to define the remaining requirements for clinical trials 

· Corporate SG&A expenses


Copyright © 2018 ALTUCELL - All Rights Reserved